title: Cancer pharmacogenomics: early promise, but concerted effort needed.
abstract: The past decade has brought together substantial advances in human genome analysis and a maturation of understanding of tumor biology. Although there is much progress still to be made, there are now several prominent examples in which tumor-associated somatic mutations have been used to identify cellular signaling pathways in tumors. This in turn has led to the development of targeted therapies, with somatic mutations serving as genomic predictors of tumor response and providing new leads for drug development. There is also a realization that germline DNA variants can help optimize cancer drug dosing and predict the susceptibility of patients to the adverse side effects of these drugs-knowledge that ultimately can be used to improve the benefit:risk ratio of cancer treatment for individual patients.
authors.affiliation: Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC 27599, USA. hmcleod@unc.edu
authors.forename: Howard L
authors.initials: HL
authors.lastname: McLeod
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D054316:Biomarkers, Pharmacological; D014408:Biomarkers, Tumor / Q000235:genetics*; D015195:Drug Design; D005260:Female; D005819:Genetic Markers; D015894:Genome, Human; D018095:Germ-Line Mutation; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D054316:Biomarkers, Pharmacological; D014408:Biomarkers, Tumor; D005819:Genetic Markers
references.citation: Science. 2013 Feb 1;339(6119):543-8
references.pmid: 23239622
references.citation: Clin Pharmacol Ther. 2012 Oct;92(4):425-7
references.pmid: 22910437
references.citation: Nat Genet. 2009 Dec;41(12):1345-9
references.pmid: 19898482
references.citation: J Clin Oncol. 2008 Apr 1;26(10):1626-34
references.pmid: 18316791
references.citation: Nat Med. 2012 Feb 12;18(3):382-4
references.pmid: 22327622
references.citation: Pharmacogenomics. 2011 Oct;12(10):1407-15
references.pmid: 22008047
references.citation: J Clin Oncol. 2012 May 1;30(13):1422-8
references.pmid: 21900104
references.citation: BMJ. 2010 Feb 08;340:c693
references.pmid: 20142325
references.citation: Clin Cancer Res. 2012 Jan 15;18(2):577-84
references.pmid: 22142827
references.citation: Clin Cancer Res. 2012 Sep 15;18(18):5099-109
references.pmid: 22843789
references.citation: Oncologist. 2012;17(5):620-30
references.pmid: 22531359
references.citation: J Clin Oncol. 2011 Aug 20;29(24):3232-9
references.pmid: 21768473
references.citation: N Engl J Med. 2011 Mar 24;364(12):1144-53
references.pmid: 21428770
references.citation: Mol Cancer Ther. 2009 Jan;8(1):10-6
references.pmid: 19139108
references.citation: Clin Pharmacol Ther. 2011 Mar;89(3):464-7
references.pmid: 21270786
references.citation: Science. 2004 Jun 4;304(5676):1497-500
references.pmid: 15118125
references.citation: J Natl Compr Canc Netw. 2011 Dec;9 Suppl 6:S1-16
references.pmid: 22203777
references.citation: J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64
references.pmid: 14652237
references.citation: J Pathol. 2011 Jan;223(1):15-27
references.pmid: 20818641
references.citation: Pharmacogenomics. 2012 Apr;13(6):691-7
references.pmid: 22515611
references.citation: Breast Cancer Res Treat. 2012 Jul;134(1):401-10
references.pmid: 22527101
references.citation: Lancet. 2000 Nov 11;356(9242):1667-71
references.pmid: 11089838
references.citation: Clin Cancer Res. 2012 Oct 15;18(20):5780-7
references.pmid: 22850565
references.citation: Clin Cancer Res. 2006 Jun 1;12(11 Pt 2):3612s-6s
references.pmid: 16740794
references.citation: Clin Pharmacol Ther. 2010 Dec;88(6):814-7
references.pmid: 20981001
references.citation: Pharmacogenet Genomics. 2012 Nov;22(11):796-802
references.pmid: 23047291